{ "@context": "https://clearank.com/llms.txt", "@type": "clearank:AssetAnalysis", "url": "https://clearank.com/stock/novartis-nvs/", "dataUrl": "https://clearank.com/stock/novartis-nvs/data.json", "title": "Novartis (NVS) Stock Forecast & Price Target (2026)", "description": "NVS stock forecast 2026: is Novartis a buy? Analysts' median price target is $156 (1% downside). CleaRank Financial AI rates it Buy, 69/100. Updated daily.", "headline": "Novartis (NVS)", "published": "2026-10-25T15:05:47.560097+00:00", "modified": "2026-10-27T23:11:16.931+00:00", "generated": "2026-10-28T03:26:28.754Z", "language": "en-US", "publisher": { "name": "CleaRank", "url": "https://clearank.com/" }, "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by Michelle Sofia, Market Analyst; prices delayed up to 15 minutes.", "asset": { "ticker": "NVS", "name": "Novartis", "type": "American Depositary Receipt", "exchange": "NYSE", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers - General", "country": "Switzerland", "website": "https://www.novartis.com" }, "quote": { "price": 156.86, "previousClose": 153.81, "change": 3.05, "changePercent": 1.98, "open": 154.14999, "high": 156.98, "low": 154.14999, "volume": 3734180, "averageVolume": 2269968, "marketCap": 298146129802, "fiftyTwoWeekHigh": 170.46001, "fiftyTwoWeekLow": 121.57, "marketOpen": false, "asOf": "2026-10-27T23:11:16.000Z" }, "statistics": { "pe": 23.69, "eps": 6.62, "dividendYield": 0.030435199061889726, "beta": 0.468, "priceToSales": 5.259, "priceToBook": 6.914348, "revenueTtm": 56692998144, "grossMargin": 0.7518560631395893, "returnOnEquity": 0.3035 }, "technicals": { "rsi": 65.32, "macd": 2.56, "sma50": 148.27, "sma200": 151.57, "rsiSignal": "Bullish", "trend": "Bearish", "pricePosition": "Bullish", "macdSignal": "Bullish", "rating": "Bullish" }, "analysis": { "rating": "Buy", "score": 69, "consensus": "Buy", "fairValue": null, "analystTarget": 156, "analystCount": 12, "wallStreetConsensus": "Buy", "generatedAt": "2026-10-27T23:11:16.000Z", "priceAtAnalysis": 156.86, "volatility": { "daily": 1.36, "risk": "standard" } }, "tradePlan": { "bias": "Bullish", "conservativeEntry": 153.72, "aggressiveEntry": 156.86, "stopLoss": 149.11, "stopLossPercent": 3, "targets": [ 161.41, 169.1, 176.78 ] }, "projections": { "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets", "years": [ { "year": 2027, "downside10th": 129.66, "base": 168.53, "upside90th": 219.04 }, { "year": 2028, "downside10th": 124.98, "base": 181.07, "upside90th": 262.34 }, { "year": 2029, "downside10th": 123.54, "base": 194.54, "upside90th": 306.35 }, { "year": 2030, "downside10th": 123.73, "base": 209.01, "upside90th": 353.09 } ] }, "faqCount": 10, "atAGlance": { "asOf": "October 27, 2026", "rating": "Buy", "score": 69, "evidence": [ { "label": "Trend", "text": "Up: the price is above both its 50- and 200-day moving averages ($148.27 and $151.57)." }, { "label": "Earnings", "text": "NVS beat estimates in 5 of its last 7 quarters, yet fell the next day after 3 of those beats." }, { "label": "Valuation", "text": "P/E of 23.7 against 31.9 for the Healthcare sector: a discount to peers (-26%)." } ] }, "figures": { "asOf": "October 27, 2026", "earningsReaction": { "quarters": 7, "beats": 5, "fellFirstSessionAfterBeat": 3, "latestReport": "Jul 21, 2026", "latestSurprisePercent": 12.09, "latestFirstSessionMovePercent": -0.51 }, "insiders": null, "drawdown": { "years": 10, "worstFallPercent": -21.81, "peak": "February 2020", "trough": "March 2020", "recoveredBy": "December 2020", "recoveryMonths": 9, "belowThatPeakNowPercent": null, "fromHighNowPercent": -6.97, "oneYearHoldsPositivePercent": 83, "dividendsReinvested": true }, "seasonality": { "years": 10, "bestMonth": { "month": "Nov", "averagePercent": 2.59, "upYearsPercent": 70 }, "worstMonth": { "month": "Sep", "averagePercent": -2.43, "upYearsPercent": 40 } }, "correlations": null, "analystTargets": { "analysts": 12, "low": 130, "median": 156, "high": 185, "mean": 154.65, "buy": 5, "hold": 5, "sell": 2 }, "dividend": { "yieldPercent": 3.04, "annualPerShare": 4.77 }, "simulation": { "year": 2030, "base": 209.01, "percentile10": 123.73, "percentile90": 353.09, "note": "Monte Carlo simulation outcomes, not price targets" } }, "sources": [ "TwelveData", "Wall Street consensus" ], "sections": [ { "id": "ch-overview", "title": "NVS stock forecast today", "text": [ "Where NVS stands today, and what CleaRank Financial AI makes of it.", "Novartis (NVS): Buy, 69/100 on CleaRank's AI score.", "Figures as of October 27, 2026.", "NVS, the Novartis stock, earns a Buy rating from CleaRank with a model score of 69/100. Momentum is the largest contributor: the 14-day RSI of 65.3 sits in the bullish zone and the MACD line is positive. Slower revenue growth holds the score back most, as revenue grew 0.80%, 7.3 percentage points slower than the sector median. The trend is up, with the price 5.80% above its 50-day average of $148.27 and 3.49% above its 200-day average of $151.57. The price has risen 21.47% over the past year.", "Figures we compute ourselves from NVS's own price, earnings and insider-filing history. Tap one to see it in context." ], "lists": { "NVS at a glance": [ "Trend Up: the price is above both its 50- and 200-day moving averages ($148.27 and $151.57).", "Earnings NVS beat estimates in 5 of the 7 reports in our data, yet fell the next day after 3 of those beats.", "Valuation P/E of 23.7 against 31.9 for the Healthcare sector: a discount to peers (-26%)." ] } }, { "id": "ch-price", "title": "NVS stock price and trading", "text": [ "The chart, today's range and how far the price has moved over each period.", "Pick a period: each tab shows how far NVS has moved over it, to the last close.", "Where NVS sits inside today's range and its 52-week range." ], "lists": { "items": [ "Price above its 50-day average › The price of $156.86 is 5.8% above the 50-day simple moving average of $148.27.", "Price above its 200-day average › The price is 3.5% above the 200-day simple moving average of $151.57.", "50-day average above the 200-day › The 50-day average ($148.27) is 2.2% below the 200-day average ($151.57), the arrangement of a falling longer-term trend.", "In the upper half of its 52-week range › The price sits at 72% of its 52-week range, between $121.57 and $170.46." ] } }, { "id": "ch-fundamentals", "title": "NVS fundamentals and valuation", "text": [ "Valuation against the sector, and the revenue and earnings behind it.", "The headline figures for NVS.", "As of October 27, 2026, NVS trades at $156.86, with a market value of $298.15B, a P/E ratio of 23.69 and a dividend yield of 3.04%.", "CleaRank Financial AI's reading of NVS's valuation, growth and risks.", "NVS trades at a trailing P/E of 23.69, against a Healthcare median of 31.9. That places the P/E 25.7% below the sector median P/E, and the peer comparison on this page rates it as a discount to peers. On sales, the P/S of 5.26 sits 54.7% above the sector median of 3.4. Year on year, revenue grew 0.80% in the latest quarter, leaving it 7.3 percentage points behind the Healthcare sector median of 8.1%. On profitability, the net margin stands at 22.50% and the operating margin at 34.62%. Return on equity is 30.35%, above the sector median of 7.3%. Debt-to-equity is 1.17, and the trailing dividend yield is 3.04%, or $4.77 a share a year.", "NVS reported EPS of $2.41 in its most recent report, dated July 21, 2026, versus an estimate of $2.15. That was a beat of 12.09%. Even so, the share price dropped 0.51% in the next session. Over the 7 reports in our data, NVS topped the estimate 5 times, but beats have not guaranteed gains: the stock fell the next day after 3 of them. Looking ahead, analysts expect EPS of $8.83 this fiscal year (a decline of 1.7%) and $9.80 the year after (growth of 11.0%).", "NVS has a beta of 0.47 against the S&P 500, and the 30-day standard deviation of its daily returns is 1.36%.", "How NVS compares with the median Healthcare stock CleaRank tracks.", "Price to earnings vs sector: NVS trades at a notable discount to sector peers (-26%), which may indicate undervaluation or specific company headwinds.", "Return vs XLV: Since May 14, 2025, NVS has gained 46.5% against a gain of 39.2% for XLV.", "NVS and the Healthcare sector fund over the same days.", "How much NVS sells, and how much of it becomes profit.", "Revenue growth: Revenue grew 9.6% in FY2025 to $56.7B, from $51.7B a year earlier.", "Profit margin: The net margin was 24.6% in FY2025, up from 23.1% the year before.", "Profitable: NVS earned $14.0B in FY2025.", "Did NVS beat what analysts expected, and how did the stock react?", "Earnings record: NVS beat the analyst estimate in 5 of the 7 reports in our data.", "Market reaction: The stock fell in the first session after 3 of those 5 beats, so a beat has not been enough on its own.", "As of October 27, 2026, NVS has beaten the analyst EPS estimate in 5 of the 7 reports in our data and fell in the first trading session after 3 of those beats; its latest report, on July 21, 2026, came in 12.09% above the estimate and the stock moved -0.51% in the first session.", "The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate." ], "tables": [ { "caption": "NVS earnings surprises and the stock's reaction", "columns": [ "Report", "Estimate", "Actual", "Surprise", "First sessionDay 1", "5 sessionsDay 5" ], "rows": [ { "label": "Jul 21, 2026after close", "cells": [ "$2.15", "$2.41", "+12.09%", "-0.51%", "+3.89%" ] }, { "label": "Apr 28, 2026after close", "cells": [ "$1.65", "$1.65", "+0.00%", "-1.76%", "+0.00%" ] }, { "label": "Oct 28, 2025after close", "cells": [ "$2.31", "$2.25", "-2.60%", "-1.32%", "+1.28%" ] }, { "label": "Jul 17, 2025after close", "cells": [ "$2.37", "$2.42", "+2.11%", "-0.24%", "+2.57%" ] }, { "label": "Apr 29, 2025after close", "cells": [ "$2.17", "$2.28", "+5.07%", "+0.04%", "-2.56%" ] }, { "label": "Jan 31, 2025after close", "cells": [ "$1.76", "$1.98", "+12.50%", "+0.73%", "+1.47%" ] }, { "label": "Oct 29, 2024after close", "cells": [ "$1.93", "$2.06", "+6.74%", "-0.56%", "-1.04%" ] } ] } ], "lists": { "items": [ "P/E below the sector median › The trailing P/E of 23.69 is 25.7% below the Healthcare median of 31.9.", "P/S below the sector median › The price-to-sales ratio of 5.26 is 54.7% above the sector median of 3.4.", "Profitable over the last 12 months › Net income over the last 12 months was $12.8B on revenue of $56.7B, a net margin of 22.5%.", "Beat estimates in most recent reports › NVS beat the EPS estimate in 5 of the 7 reports in our data.", "Pays a dividend › The trailing dividend yield is 3.04%, or $4.77 a share a year." ] } }, { "id": "ch-analysis", "title": "NVS AI analysis and technical indicators", "text": [ "CleaRank's score and reasoning, the indicators behind it, and what the price moves with.", "The score, the reasoning behind it, and what could move the price next.", "NVS is in an uptrend: the price of $156.86 sits 3.49% above its 200-day average of $151.57 and 5.80% above its 50-day average of $148.27. The price is at 72% of its 52-week range, and 7.98% below the 52-week high of $170.46. Both averages still lag the price, with the 50-day 2.18% below the 200-day. The 14-day RSI sits at 65.3, which is in the bullish zone without reaching overbought territory, and the MACD line is positive. Over the short and long run the picture diverges: the price rose 7.84% over the past month and 21.47% over the past year, but fell 1.87% over the past three months. In the last session the price rose 1.98%, with volume 64.5% above its average.", "HSBC upgraded it to Hold from Reduce on September 10, 2026.", "The July 21, 2026 report beat the EPS estimate by 12.09%, and the share price fell 0.51% in the first session after it.", "NVS trades above its 50-day and 200-day moving averages ($148.27 and $151.57), which is what makes the trend up; losing the 200-day would be the first warning. The nearest level under the price is the 200-day SMA at $151.57. The next level overhead for NVS is the 52-week high at $170.46. The RSI is in the bullish band, supporting the current direction while sitting near the overbought threshold.", "Momentum and trend for NVS, from its daily closes.", "As of October 27, 2026, with NVS at $156.86, its 14-day RSI is 65.3 (showing bullish momentum without being overbought), its 50-day simple moving average is $148.27 and its 200-day is $151.57.", "Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these", "Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.", "As of October 27, 2026, NVS's 1-year correlation of daily returns is +0.16 with S&P 500 (SPY), +0.03 with Nasdaq 100 (QQQ), +0.05 with Bitcoin (BTC) and +0.14 with gold (XAU)." ], "lists": { "items": [ "RSI Bullish", "SMA cross Bearish", "Price vs SMA Bullish", "MACD Bullish" ] }, "links": [ { "text": "HSBC", "url": "https://clearank.com/stock/hsbc-hsbc/" } ] }, { "id": "ch-street", "title": "NVS price target and analyst forecast", "text": [ "The analysts' target range and how their ratings split.", "As of October 27, 2026, 12 Wall Street analysts cover NVS: 5 rate it a buy or strong buy, 5 a hold and 2 a sell or strong sell. Their 12-month price targets range from $130.00 to $185.00. The median NVS price target is $156.00, 0.5% below the price of $156.86.", "Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank." ], "tables": [ { "caption": "Recent analyst rating actions on NVS", "columns": [ "Date", "Firm", "Action", "Rating" ], "rows": [ { "label": "Sep 10, 2026", "cells": [ "HSBC", "Upgrade", "Hold" ] } ] } ], "lists": { "items": [ "Most analysts rate it a buy › 5 of 12 analysts rate it a buy or strong buy, 5 a hold and 2 a sell.", "Median target above the price › The median 12-month target of $156.00 is 0.5% below the price.", "More buy ratings than three months ago › 5 of 12 rate it a buy now, against 5 of 12 three months ago." ] } }, { "id": "ch-plan", "title": "NVS trade plan: entry, stop loss and targets", "text": [ "Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.", "Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.", "Lower risk, wait for pullback", "Higher risk, immediate entry", "These levels come from NVS's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.", "Would this NVS plan have made money the last ten times?", "Your entry, stop and targets are set above. Replay them against NVS's own history and count how often the target hit before the stop.", "How much NVS tends to move, against the market and on its own." ], "lists": { "items": [ "Wins vs stops", "Best exit", "Max drawdown" ] }, "links": [ { "text": "Position Size", "url": "https://clearank.com/tools/position-size-calculator/" }, { "text": "Stop Loss", "url": "https://clearank.com/tools/stop-loss-calculator/" }, { "text": "Risk/Reward", "url": "https://clearank.com/tools/risk-reward-calculator/" }, { "text": "P&L Calculator", "url": "https://clearank.com/tools/profit-loss-calculator/" }, { "text": "Trailing Stop", "url": "https://clearank.com/tools/trailing-stop-calculator/" }, { "text": "Fibonacci", "url": "https://clearank.com/tools/fibonacci-calculator/" }, { "text": "Pivot Points", "url": "https://clearank.com/tools/pivot-point-calculator/" }, { "text": "Win Rate", "url": "https://clearank.com/tools/breakeven-win-rate-calculator/" }, { "text": "Expectancy", "url": "https://clearank.com/tools/trade-expectancy-calculator/" }, { "text": "Replay this plan on NVSStart free trial · $0 today", "url": "https://trade.clearank.com/portfolio/demo?utm_source=clearank&utm_medium=cta&utm_campaign=asset_plan&utm_content=trial7" } ] }, { "id": "ch-risk", "title": "NVS price history and drawdowns", "text": [ "NVS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.", "As of October 27, 2026, NVS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -21.8% (February 2020 to March 2020); it regained that peak by December 2020, 9 months after the low, and 83% of 1-year holding periods ended with a gain.", "From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.", "What $10,000 put into NVS in October 2016 is worth now, against the same amount in the S&P 500.", "Against the market: NVS trailed the S&P 500 over this period: $33,982 against $42,015.", "A $10,000 investment in NVS in October 2016 would be worth about $33,982 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).", "Which calendar months have been kind to NVS, and which have not.", "Strongest month, November: an average of +2.59%, up in 7 of 10 years.", "Weakest month, September: an average of -2.43%, up in 4 of 10 years.", "This month, October: has averaged -1.59%, up in 4 of 9 years. Past seasonality does not repeat on schedule.", "Over the last 10 years, NVS's strongest calendar month has been November (average +2.59%, up in 7 of 10 years) and its weakest September (average -2.43%, up in 4 of 10 years).", "Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included." ], "lists": { "items": [ "Average daily move under 2% › The price has moved 1.36% on an average day (30-day standard deviation of daily returns).", "Recovered from its worst fall › The worst fall was 21.8%, from February 2020 to March 2020, regained by December 2020.", "Most 1-year holds ended higher › 83% of 1-year holding periods in the last 10 years ended with a gain.", "Beat the S&P 500 since the chart begins › $10,000 invested in October 2016 is now worth $33,982, against $42,015 in the S&P 500 (SPY)." ] } }, { "id": "ch-scenarios", "title": "NVS stock price prediction 2030", "text": [ "Thousands of simulated paths from the price history. A range of outcomes, not a forecast.", "Thousands of simulated paths for $10,000 in NVS, from its own past volatility. The shaded area holds 80% of them.", "CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in NVS today could grow to about $13,325 by 2030 in the base case, with a 90th-percentile outcome near $22,510 and a 10th-percentile outcome around $7,888. The simulation models price only; at today's 3.04% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.", "The same simulation in share prices, year by year.", "CleaRank's simulation projects a price near $209 for NVS by 2030 in the base case, from $157 today (1.3x over 4 years). The 10th-percentile path ends near $124. These are outcomes of a Monte Carlo simulation run on NVS's historical return distribution, not price targets, and they assume no dividends are reinvested.", "Method: a lognormal simulation of NVS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works", "What would NVS do to your portfolio?", "Add it to what you already hold. Ten-year backtest, the drawdown it brings, and how much of it is just the S&P in disguise." ], "tables": [ { "caption": "NVS simulated price paths by year", "columns": [ "Year", "10th percentile", "Base case", "90th percentile", "range base today" ], "rows": [ { "label": "2027", "cells": [ "$130", "$169", "$219", "" ] }, { "label": "2028", "cells": [ "$125", "$181", "$262", "" ] }, { "label": "2029", "cells": [ "$124", "$195", "$306", "" ] }, { "label": "2030", "cells": [ "$124", "$209", "$353", "" ] } ] } ], "lists": { "items": [ "10-year backtest", "Drawdown added", "Correlation" ] }, "links": [ { "text": "Backtest my portfolio with NVSStart free trial · $0 today", "url": "https://trade.clearank.com/portfolio/demo?utm_source=clearank&utm_medium=cta&utm_campaign=asset_longterm&utm_content=trial7" } ] }, { "id": "ch-faq", "title": "NVS stock forecast: questions people ask", "text": [ "Answered from the figures on this page, as of October 27, 2026." ] }, { "id": "ch-related", "title": "Compare NVS with similar assets", "text": [ "Assets people compare with this one." ], "links": [ { "text": "AGL agilon health, inc. NYSE $90.65 +0.34%", "url": "https://clearank.com/stock/agl-stock-analysis/" }, { "text": "AZN AstraZeneca NASDAQ $170.05 -1.17%", "url": "https://clearank.com/stock/astrazeneca-azn/" }, { "text": "ABT Abbott Laboratories NYSE $103.10 -1.70%", "url": "https://clearank.com/stock/abbott-laboratories-abt/" }, { "text": "EW Edwards Lifesciences Corp NYSE $90.82 +0.29%", "url": "https://clearank.com/stock/ew-stock-analysis/" }, { "text": "BSX Boston Scientific Corp NYSE $45.08 -1.11%", "url": "https://clearank.com/stock/boston-scientific-bsx/" }, { "text": "ZTS Zoetis Inc. NYSE $80.97 -0.07%", "url": "https://clearank.com/stock/zts-stock-analysis/" }, { "text": "TLRY Tilray Brands Inc. NASDAQ $2.72 -3.20%", "url": "https://clearank.com/stock/tilray-brands-tlry/" }, { "text": "VRTX Vertex Pharmaceuticals Incorporated NASDAQ $517.49 -1.23%", "url": "https://clearank.com/stock/vertex-vrtx/" }, { "text": "SPY vs VOO Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/spy-vs-voo/" }, { "text": "VTI vs VT Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/vti-vs-vt/" }, { "text": "QQQ vs SCHG Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/qqq-vs-schg/" } ] } ], "faq": [ { "question": "Is Novartis (NVS) a buy right now?", "answer": "The Buy rating comes from a model score of 69/100. Most of the lift comes from momentum, as the 14-day RSI of 65.3 is in the bullish zone and the MACD line is positive. The biggest drag is revenue growth: revenue grew 0.80%, 7.3 percentage points slower than the sector median. This describes the data on this page and is not a personal recommendation." }, { "question": "How has Novartis (NVS) performed over the past year?", "answer": "The price has climbed 21.47% across the past year. Over shorter spans, it dropped 1.87% over three months but gained 7.84% in the last month. The stock currently sits 7.98% under its 52-week high of $170.46." }, { "question": "What are the key price levels for NVS?", "answer": "The nearest level above the price is the 52-week high at $170.46. Below the price, the first levels are the 200-day SMA at $151.57 and the 20-day EMA at $149.52." }, { "question": "Is NVS expensive compared with Healthcare stocks?", "answer": "At a trailing P/E of 23.69, NVS is 25.7% below the Healthcare median of 31.9, and the peer comparison on this page labels that a discount to peers." }, { "question": "Does NVS pay a dividend?", "answer": "Yes, NVS pays a trailing dividend yield of 3.04%, which works out to $4.77 per share each year. The yield is the annual dividend divided by the share price, so it moves whenever either of those moves." }, { "question": "What do Wall Street analysts think of NVS?", "answer": "Among the 12 analysts who cover NVS, 5 recommend buying, 5 recommend holding and 2 recommend selling. The median 12-month price target is $156.00, which is 0.5% under the current price." }, { "question": "How often has NVS beaten earnings estimates?", "answer": "In the 7 most recent reports in our data, NVS beat the EPS estimate in 5 of them. The share price fell in the first session after 3 of those 5 beats." }, { "question": "How volatile is NVS?", "answer": "On an average day NVS's price moves 1.36%, based on the 30-day standard deviation of daily returns. Measured against the S&P 500, its beta is 0.47." }, { "question": "What is the 52-week range of NVS?", "answer": "Over the past 52 weeks, NVS has moved between $121.57 and $170.46. At $156.86, the stock is at 72% of that span, 29.03% above the low and 7.98% below the high." }, { "question": "Is NVS in an uptrend?", "answer": "Yes. Novartis (NVS) trades at $156.86, above both its 50- and 200-day moving averages ($148.27 and $151.57). Its 14-day RSI on daily closes is 65.3, showing bullish momentum without being overbought." } ], "related": { "peopleAlsoWatch": [ { "ticker": "AGL", "name": "agilon health, inc. NYSE", "price": "$90.65", "change": "+0.34%", "url": "https://clearank.com/stock/agl-stock-analysis/" }, { "ticker": "AZN", "name": "AstraZeneca NASDAQ", "price": "$170.05", "change": "-1.17%", "url": "https://clearank.com/stock/astrazeneca-azn/" }, { "ticker": "ABT", "name": "Abbott Laboratories NYSE", "price": "$103.10", "change": "-1.70%", "url": "https://clearank.com/stock/abbott-laboratories-abt/" }, { "ticker": "EW", "name": "Edwards Lifesciences Corp NYSE", "price": "$90.82", "change": "+0.29%", "url": "https://clearank.com/stock/ew-stock-analysis/" }, { "ticker": "BSX", "name": "Boston Scientific Corp NYSE", "price": "$45.08", "change": "-1.11%", "url": "https://clearank.com/stock/boston-scientific-bsx/" }, { "ticker": "ZTS", "name": "Zoetis Inc. NYSE", "price": "$80.97", "change": "-0.07%", "url": "https://clearank.com/stock/zts-stock-analysis/" }, { "ticker": "TLRY", "name": "Tilray Brands Inc. NASDAQ", "price": "$2.72", "change": "-3.20%", "url": "https://clearank.com/stock/tilray-brands-tlry/" }, { "ticker": "VRTX", "name": "Vertex Pharmaceuticals Incorporated NASDAQ", "price": "$517.49", "change": "-1.23%", "url": "https://clearank.com/stock/vertex-vrtx/" } ], "comparisons": [ { "ticker": "SPY vs VOO Comparison", "name": "", "url": "https://clearank.com/compare/spy-vs-voo/" }, { "ticker": "VTI vs VT Comparison", "name": "", "url": "https://clearank.com/compare/vti-vs-vt/" }, { "ticker": "QQQ vs SCHG Comparison", "name": "", "url": "https://clearank.com/compare/qqq-vs-schg/" } ], "Newly Tracked": [ { "ticker": "AZN", "text": "AstraZeneca", "url": "https://clearank.com/stock/astrazeneca-azn/" }, { "ticker": "ZBH", "text": "Zimmer Biomet Holdings Inc.", "url": "https://clearank.com/stock/zimmer-biomet-zbh/" }, { "ticker": "SONY", "text": "Sony Group", "url": "https://clearank.com/stock/sony-sony/" }, { "ticker": "HSBC", "text": "HSBC Holdings", "url": "https://clearank.com/stock/hsbc-hsbc/" }, { "ticker": "SHEL", "text": "Shell", "url": "https://clearank.com/stock/shell-shel/" } ], "Top Movers (24h)": [ { "ticker": "AMKR", "text": "↑ 8.50%", "url": "https://clearank.com/stock/amkor-amkr/" }, { "ticker": "RKLB", "text": "↑ 8.34%", "url": "https://clearank.com/stock/rocket-lab-rklb/" }, { "ticker": "INOD", "text": "↓ 25.32%", "url": "https://clearank.com/stock/inod-stock-analysis/" }, { "ticker": "NU", "text": "↓ 16.95%", "url": "https://clearank.com/stock/nu-holdings-nu/" }, { "ticker": "SOFI", "text": "↑ 13.42%", "url": "https://clearank.com/stock/sofi-technologies-sofi/" } ], "Also in Healthcare": [ { "ticker": "JNJ", "text": "Johnson & Johnson", "url": "https://clearank.com/stock/johnson-johnson-jnj/" }, { "ticker": "LLY", "text": "Eli Lilly", "url": "https://clearank.com/stock/eli-lilly-lly/" }, { "ticker": "MRK", "text": "Merck", "url": "https://clearank.com/stock/merck-mrk/" }, { "ticker": "NVO", "text": "Novo Nordisk", "url": "https://clearank.com/stock/novo-nordisk-nvo/" }, { "ticker": "PFE", "text": "Pfizer", "url": "https://clearank.com/stock/pfizer-pfe/" } ] }, "schema": [ { "@context": "https://schema.org", "@graph": [ { "@type": "Place", "@id": "https://clearank.com/#place", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" } }, { "@type": "Organization", "@id": "https://clearank.com/#organization", "name": "CleaRank", "alternateName": "CleaRank Financial AI", "url": "https://clearank.com", "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), with a 7-day free trial, which combines a trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.", "slogan": "Clear data. Honest analysis.", "logo": { "@type": "ImageObject", "@id": "https://clearank.com/#logo", "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "caption": "CleaRank", "inLanguage": "en-US", "width": "336", "height": "153" }, "image": { "@id": "https://clearank.com/#logo" }, "sameAs": [ "https://x.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank", "https://t.me/clearank" ], "email": "info@clearank.com", "contactPoint": [ { "@type": "ContactPoint", "contactType": "customer support", "email": "info@clearank.com", "url": "https://clearank.com/contact/", "availableLanguage": "en" } ], "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" }, "location": { "@id": "https://clearank.com/#place" }, "knowsAbout": [ "stock analysis", "ETF analysis", "cryptocurrency analysis", "forex trading", "trading simulation", "trade journaling", "position sizing", "risk management", "prop firm challenges", "online broker regulation" ], "publishingPrinciples": "https://clearank.com/editorial-code/", "ethicsPolicy": "https://clearank.com/editorial-code/", "ownershipFundingInfo": "https://clearank.com/about-us/", "owns": { "@id": "https://clearank.com/#app" }, "founder": { "@id": "https://clearank.com/writer/shaundavidb/#person" } }, { "@type": "WebSite", "@id": "https://clearank.com/#website", "url": "https://clearank.com", "name": "CleaRank", "publisher": { "@id": "https://clearank.com/#organization" }, "inLanguage": "en-US" }, { "@type": "ImageObject", "@id": "https://clearank.com/og/mi/stock/novartis-nvs.png", "url": "https://clearank.com/og/mi/stock/novartis-nvs.png", "width": "1200", "height": "630", "caption": "Novartis (NVS) analysis by CleaRank", "inLanguage": "en-US" }, { "@type": "BreadcrumbList", "@id": "https://clearank.com/stock/novartis-nvs/#breadcrumb", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "https://clearank.com", "name": "Home" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "https://clearank.com/stock/", "name": "Stocks" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "https://clearank.com/stock/novartis-nvs/", "name": "Novartis (NVS)" } } ] }, { "@type": "WebPage", "@id": "https://clearank.com/stock/novartis-nvs/#webpage", "url": "https://clearank.com/stock/novartis-nvs/", "name": "Novartis (NVS) Stock Forecast & Price Target (2026)", "datePublished": "2026-10-25T15:05:47+00:00", "dateModified": "2026-10-27T23:11:16+00:00", "isPartOf": { "@id": "https://clearank.com/#website" }, "primaryImageOfPage": { "@id": "https://clearank.com/og/mi/stock/novartis-nvs.png" }, "inLanguage": "en-US", "breadcrumb": { "@id": "https://clearank.com/stock/novartis-nvs/#breadcrumb" }, "reviewedBy": { "@id": "https://clearank.com/writer/michelle-sofia/#person" } }, { "@type": "Person", "@id": "https://clearank.com/writer/michelle-sofia/#person", "name": "Michelle Sofia", "jobTitle": "Market Analyst", "url": "https://clearank.com/writer/michelle-sofia/", "worksFor": { "@id": "https://clearank.com/#organization" } }, { "@type": "Article", "@id": "https://clearank.com/stock/novartis-nvs/#richSnippet", "headline": "Novartis (NVS) Stock Forecast & Price Target (2026)", "name": "Novartis (NVS) Stock Forecast & Price Target (2026)", "description": "NVS stock forecast 2026: is Novartis a buy? Analysts' median price target is $156 (1% downside). CleaRank Financial AI rates it Buy, 69/100. Updated daily.", "datePublished": "2026-10-25T15:05:47+00:00", "dateModified": "2026-10-27T23:11:16+00:00", "author": { "@id": "https://clearank.com/#organization" }, "publisher": { "@id": "https://clearank.com/#organization" }, "publishingPrinciples": "https://clearank.com/market-insights/methodology/", "about": { "@type": "Corporation", "name": "Novartis", "identifier": [ { "@type": "PropertyValue", "propertyID": "tickerSymbol", "value": "NVS" }, { "@type": "PropertyValue", "propertyID": "exchange", "value": "NYSE" } ], "description": "Novartis AG Sponsored ADR represents Novartis AG, a global healthcare company focused on developing, manufacturing, and commercializing prescription medicines and related healthcare products. Novartis serves major therapeutic areas including oncology, immunology, cardiovascular, neuroscience, and op", "tickerSymbol": "NVS", "sameAs": "https://www.novartis.com" }, "isPartOf": { "@id": "https://clearank.com/stock/novartis-nvs/#webpage" }, "image": { "@id": "https://clearank.com/og/mi/stock/novartis-nvs.png" }, "inLanguage": "en-US", "mainEntityOfPage": { "@id": "https://clearank.com/stock/novartis-nvs/#webpage" } } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is Novartis (NVS) a buy right now?", "acceptedAnswer": { "@type": "Answer", "text": "The Buy rating comes from a model score of 69/100. Most of the lift comes from momentum, as the 14-day RSI of 65.3 is in the bullish zone and the MACD line is positive. The biggest drag is revenue growth: revenue grew 0.80%, 7.3 percentage points slower than the sector median. This describes the data on this page and is not a personal recommendation." } }, { "@type": "Question", "name": "How has Novartis (NVS) performed over the past year?", "acceptedAnswer": { "@type": "Answer", "text": "The price has climbed 21.47% across the past year. Over shorter spans, it dropped 1.87% over three months but gained 7.84% in the last month. The stock currently sits 7.98% under its 52-week high of $170.46." } }, { "@type": "Question", "name": "What are the key price levels for NVS?", "acceptedAnswer": { "@type": "Answer", "text": "The nearest level above the price is the 52-week high at $170.46. Below the price, the first levels are the 200-day SMA at $151.57 and the 20-day EMA at $149.52." } }, { "@type": "Question", "name": "Is NVS expensive compared with Healthcare stocks?", "acceptedAnswer": { "@type": "Answer", "text": "At a trailing P/E of 23.69, NVS is 25.7% below the Healthcare median of 31.9, and the peer comparison on this page labels that a discount to peers." } }, { "@type": "Question", "name": "Does NVS pay a dividend?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, NVS pays a trailing dividend yield of 3.04%, which works out to $4.77 per share each year. The yield is the annual dividend divided by the share price, so it moves whenever either of those moves." } }, { "@type": "Question", "name": "What do Wall Street analysts think of NVS?", "acceptedAnswer": { "@type": "Answer", "text": "Among the 12 analysts who cover NVS, 5 recommend buying, 5 recommend holding and 2 recommend selling. The median 12-month price target is $156.00, which is 0.5% under the current price." } }, { "@type": "Question", "name": "How often has NVS beaten earnings estimates?", "acceptedAnswer": { "@type": "Answer", "text": "In the 7 most recent reports in our data, NVS beat the EPS estimate in 5 of them. The share price fell in the first session after 3 of those 5 beats." } }, { "@type": "Question", "name": "How volatile is NVS?", "acceptedAnswer": { "@type": "Answer", "text": "On an average day NVS's price moves 1.36%, based on the 30-day standard deviation of daily returns. Measured against the S&P 500, its beta is 0.47." } }, { "@type": "Question", "name": "What is the 52-week range of NVS?", "acceptedAnswer": { "@type": "Answer", "text": "Over the past 52 weeks, NVS has moved between $121.57 and $170.46. At $156.86, the stock is at 72% of that span, 29.03% above the low and 7.98% below the high." } }, { "@type": "Question", "name": "Is NVS in an uptrend?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Novartis (NVS) trades at $156.86, above both its 50- and 200-day moving averages ($148.27 and $151.57). Its 14-day RSI on daily closes is 65.3, showing bullish momentum without being overbought." } } ] } ] }